Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Respiratory Syncytial Virus (RSV) Therapeutics Market Segmentation
1. Executive Summary
2. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Introduction
2.1. Global Respiratory Syncytial Virus (RSV) Therapeutics Market - Taxonomy
2.2. Global Respiratory Syncytial Virus (RSV) Therapeutics Market - Definitions
2.2.1. Drug Class
2.2.2. Distribution Channel
2.2.3. Region
3. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Key Developments
4. Global Respiratory Syncytial Virus (RSV) Therapeutics Market By Drug Class, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
4.1. Prophylaxis
4.1.1. Palivizumab
4.1.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.1.1.3. Market Opportunity Analysis
4.1.2. Nirsevimab
4.1.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.1.2.3. Market Opportunity Analysis
4.1.3. MK-1654
4.1.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.1.3.3. Market Opportunity Analysis
4.1.4. Others
4.1.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.1.4.3. Market Opportunity Analysis
4.2. Treatment
4.2.1. Ribavirin
4.2.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.2.1.3. Market Opportunity Analysis
4.2.2. JNJ 53718678
4.2.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.2.2.3. Market Opportunity Analysis
4.2.3. Enanta EDP-938
4.2.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.2.3.3. Market Opportunity Analysis
4.2.4. ASCENIV
4.2.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.2.4.3. Market Opportunity Analysis
5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market By Distribution Channel , 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Hospital Pharmacy
5 1 1 Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Retail Pharmacy
5.2.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.1.3. Market Opportunity Analysis
5.2.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.2.3. Market Opportunity Analysis
5.2.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3.3. Market Opportunity Analysis
6. Global Respiratory Syncytial Virus (RSV) Therapeutics Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. North America
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Europe
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Asia Pacific
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Latin America
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. MEA
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Global Respiratory Syncytial Virus (RSV) Therapeutics Market - Opportunity Analysis Index, By Distribution Channel , Drug Class, , , , , , and Region, 2023-2029
7. North America Respiratory Syncytial Virus (RSV) Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Drug Class Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
7.1.1. Prophylaxis
7.1.1.1. Palivizumab
7.1.1.2. Nirsevimab
7.1.1.3. MK-1654
7.1.1.4. Others
7.1.2. Treatment
7.1.2.1. Ribavirin
7.1.2.2. JNJ 53718678
7.1.2.3. Enanta EDP-938
7.1.2.4. ASCENIV
7.2. Distribution Channel Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
7.2.1. Hospital Pharmacy
7.2.2. Retail Pharmacy
7.3. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
7.3.1. USA
7.3.2. Canada
8. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. Drug Class Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.1.1. Prophylaxis
8.1.1.1. Palivizumab
8.1.1.2. Nirsevimab
8.1.1.3. MK-1654
8.1.1.4. Others
8.1.2. Treatment
8.1.2.1. Ribavirin
8.1.2.2. JNJ 53718678
8.1.2.3. Enanta EDP-938
8.1.2.4. ASCENIV
8.2. Distribution Channel Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.2.1. Hospital Pharmacy
8.2.2. Retail Pharmacy
8.3. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.3.1. Germany
8.3.2. France
8.3.3. Italy
8.3.4. Spain
8.3.5. UK
8.3.6. Rest of Europe
9. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Drug Class Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1. Prophylaxis
9.1.1.1. Palivizumab
9.1.1.2. Nirsevimab
9.1.1.3. MK-1654
9.1.1.4. Others
9.1.2. Treatment
9.1.2.1. Ribavirin
9.1.2.2. JNJ 53718678
9.1.2.3. Enanta EDP-938
9.1.2.4. ASCENIV
9.2. Distribution Channel Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1. Hospital Pharmacy
9.2.2. Retail Pharmacy
9.3. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1. China
9.3.2. Japan
9.3.3. South Korea
9.3.4. India
9.3.5. Rest of APAC
10. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Drug Class Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1. Prophylaxis
10.1.1.1. Palivizumab
10.1.1.2. Nirsevimab
10.1.1.3. MK-1654
10.1.1.4. Others
10.1.2. Treatment
10.1.2.1. Ribavirin
10.1.2.2. JNJ 53718678
10.1.2.3. Enanta EDP-938
10.1.2.4. ASCENIV
10.2. Distribution Channel Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1. Hospital Pharmacy
10.2.2. Retail Pharmacy
10.3. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Argentina
10.3.4. Rest of Latin America
11. MEA Respiratory Syncytial Virus (RSV) Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Drug Class Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1. Prophylaxis
11.1.1.1. Palivizumab
11.1.1.2. Nirsevimab
11.1.1.3. MK-1654
11.1.1.4. Others
11.1.2. Treatment
11.1.2.1. Ribavirin
11.1.2.2. JNJ 53718678
11.1.2.3. Enanta EDP-938
11.1.2.4. ASCENIV
11.2. Distribution Channel Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1. Hospital Pharmacy
11.2.2. Retail Pharmacy
11.3. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1. GCC Countries
11.3.2. South Africa
11.3.3. Rest of MEA
12. Competition Landscape
12.1. Strategic Dashboard of Top Market Players
12.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis)
12.2.1. AstraZeneca
12.2.2. AbbVie
12.2.3. Johnson and Johnson Services Inc.
12.2.4. Sanofi
12.2.5. Merck & Co., Inc.
12.2.6. Celltrion Inc.
12.2.7. mAbxience
12.2.8. Enanta PharmaceuticalS Inc.
13. Research Methodology
14. Key Assumptions and Acronyms
2. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Introduction
2.1. Global Respiratory Syncytial Virus (RSV) Therapeutics Market - Taxonomy
2.2. Global Respiratory Syncytial Virus (RSV) Therapeutics Market - Definitions
2.2.1. Drug Class
2.2.2. Distribution Channel
2.2.3. Region
3. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Key Developments
4. Global Respiratory Syncytial Virus (RSV) Therapeutics Market By Drug Class, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
4.1. Prophylaxis
4.1.1. Palivizumab
4.1.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.1.1.3. Market Opportunity Analysis
4.1.2. Nirsevimab
4.1.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.1.2.3. Market Opportunity Analysis
4.1.3. MK-1654
4.1.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.1.3.3. Market Opportunity Analysis
4.1.4. Others
4.1.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.1.4.3. Market Opportunity Analysis
4.2. Treatment
4.2.1. Ribavirin
4.2.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.2.1.3. Market Opportunity Analysis
4.2.2. JNJ 53718678
4.2.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.2.2.3. Market Opportunity Analysis
4.2.3. Enanta EDP-938
4.2.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.2.3.3. Market Opportunity Analysis
4.2.4. ASCENIV
4.2.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.2.4.3. Market Opportunity Analysis
5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market By Distribution Channel , 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Hospital Pharmacy
5 1 1 Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Retail Pharmacy
5.2.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.1.3. Market Opportunity Analysis
5.2.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.2.3. Market Opportunity Analysis
5.2.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3.3. Market Opportunity Analysis
6. Global Respiratory Syncytial Virus (RSV) Therapeutics Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. North America
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Europe
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Asia Pacific
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Latin America
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. MEA
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Global Respiratory Syncytial Virus (RSV) Therapeutics Market - Opportunity Analysis Index, By Distribution Channel , Drug Class, , , , , , and Region, 2023-2029
7. North America Respiratory Syncytial Virus (RSV) Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Drug Class Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
7.1.1. Prophylaxis
7.1.1.1. Palivizumab
7.1.1.2. Nirsevimab
7.1.1.3. MK-1654
7.1.1.4. Others
7.1.2. Treatment
7.1.2.1. Ribavirin
7.1.2.2. JNJ 53718678
7.1.2.3. Enanta EDP-938
7.1.2.4. ASCENIV
7.2. Distribution Channel Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
7.2.1. Hospital Pharmacy
7.2.2. Retail Pharmacy
7.3. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
7.3.1. USA
7.3.2. Canada
8. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. Drug Class Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.1.1. Prophylaxis
8.1.1.1. Palivizumab
8.1.1.2. Nirsevimab
8.1.1.3. MK-1654
8.1.1.4. Others
8.1.2. Treatment
8.1.2.1. Ribavirin
8.1.2.2. JNJ 53718678
8.1.2.3. Enanta EDP-938
8.1.2.4. ASCENIV
8.2. Distribution Channel Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.2.1. Hospital Pharmacy
8.2.2. Retail Pharmacy
8.3. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.3.1. Germany
8.3.2. France
8.3.3. Italy
8.3.4. Spain
8.3.5. UK
8.3.6. Rest of Europe
9. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Drug Class Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1. Prophylaxis
9.1.1.1. Palivizumab
9.1.1.2. Nirsevimab
9.1.1.3. MK-1654
9.1.1.4. Others
9.1.2. Treatment
9.1.2.1. Ribavirin
9.1.2.2. JNJ 53718678
9.1.2.3. Enanta EDP-938
9.1.2.4. ASCENIV
9.2. Distribution Channel Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1. Hospital Pharmacy
9.2.2. Retail Pharmacy
9.3. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1. China
9.3.2. Japan
9.3.3. South Korea
9.3.4. India
9.3.5. Rest of APAC
10. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Drug Class Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1. Prophylaxis
10.1.1.1. Palivizumab
10.1.1.2. Nirsevimab
10.1.1.3. MK-1654
10.1.1.4. Others
10.1.2. Treatment
10.1.2.1. Ribavirin
10.1.2.2. JNJ 53718678
10.1.2.3. Enanta EDP-938
10.1.2.4. ASCENIV
10.2. Distribution Channel Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1. Hospital Pharmacy
10.2.2. Retail Pharmacy
10.3. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Argentina
10.3.4. Rest of Latin America
11. MEA Respiratory Syncytial Virus (RSV) Therapeutics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Drug Class Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1. Prophylaxis
11.1.1.1. Palivizumab
11.1.1.2. Nirsevimab
11.1.1.3. MK-1654
11.1.1.4. Others
11.1.2. Treatment
11.1.2.1. Ribavirin
11.1.2.2. JNJ 53718678
11.1.2.3. Enanta EDP-938
11.1.2.4. ASCENIV
11.2. Distribution Channel Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1. Hospital Pharmacy
11.2.2. Retail Pharmacy
11.3. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1. GCC Countries
11.3.2. South Africa
11.3.3. Rest of MEA
12. Competition Landscape
12.1. Strategic Dashboard of Top Market Players
12.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis)
12.2.1. AstraZeneca
12.2.2. AbbVie
12.2.3. Johnson and Johnson Services Inc.
12.2.4. Sanofi
12.2.5. Merck & Co., Inc.
12.2.6. Celltrion Inc.
12.2.7. mAbxience
12.2.8. Enanta PharmaceuticalS Inc.
13. Research Methodology
14. Key Assumptions and Acronyms
• AstraZeneca
• AbbVie
• Johnson and Johnson Services Inc.
• Sanofi
• Merck & Co., Inc.
• Celltrion Inc.
• mAbxience
• Enanta PharmaceuticalS Inc.
• AbbVie
• Johnson and Johnson Services Inc.
• Sanofi
• Merck & Co., Inc.
• Celltrion Inc.
• mAbxience
• Enanta PharmaceuticalS Inc.